What You Should Know:
- Obviohealth, a decentralized clinical trial platform, has launched a new AI-assisted clinical raters platform to eliminate biases from trials.
The platform Augmented ePRO (electronic patient-reported outcomes), has been designed to assist clinical raters to better score patient outcomes, without biases.
Why It Matters
As more trials take place virtually or decentralized, clinical researchers are at the mercy of the quality of the information provided by the
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Topography Health Launches out of Stealth with $27.5M to Empower Community Physicians to Run Clinical Drug Trials
What You Should Know:
- Topography Health, a clinical trials startup focused on community physicians, today launched out of stealth with $27.5M in funding from Andreessen Horowitz and Bain Capital Ventures.
- Co-founded by former Gerson Lehrman Group CEO Alexander Saint-Amand, Topography is making it possible for your family doctor to offer clinical drug trials as part of their practice. Not just for potentially terminal illnesses, but also for moderate chronic illnesses, where the
Read More
7 Burning Questions from Life Sciences Companies on Using AI Agents
Each day life science companies respond to numerous medical information inquires – many of which are similar in nature or can be simply addressed. However, as we have seen in the news reports with the Great Resignation and many workers searching for new careers, the number of individuals interested in working in a medical information contact center may be waning. When you combine this with the rising volume of inquiries or medical inquiries and patient expectations for a real-time response to
Read More
Spatial Omics: The Next Wave in the Biological Research Revolution
For decades, biomedical researchers pursued a reductionist strategy, investigating DNA, RNA, proteins and other cellular players in isolation. These studies have been critically important, providing vital parts lists to guide further exploration. Now, however, biology has entered a new age, in which scientists must adopt more contextual approaches to understand the fundamental units of life – cells.
But to truly understand how cells operate, we must explore their relationships in time
Read More
Truepill Launches COVID-19 Test Coverage Platform
What You Should Know:
- Truepill, the digital health platform connecting telehealth, diagnostics, and pharmacy to transform consumer healthcare launches COVID-19 Test Coverage Platform, adding to its growing suite of COVID-19 solutions. The COVID-19 Test Coverage Platform is the latest tool in Truepill’s suite of COVID-19 wellness solutions, which includes an end-to-end COVID-19 testing platform and a COVID-19 virtual care platform that provides on-demand telehealth consults and
Read More
iSpecimen Expands COVID-19 Research with Sequences Specimens to Detect Variants
What You Should Know:
- iSpecimen, the developer of an online marketplace that connects human biospecimen with researchers, announced that is has expanded its supplier capabilities in support of COVID-19 researchers.
- Through a new partnership with a reference lab in New York, researchers looking to validate their own COVID variant identification assays can obtain sequenced and unsequenced COVID-19 positive and negative swabs in a variety of media types through iSpecimen. This lab is
Read More
Decentralized Clinical Trials Can Achieve Net Financial Benefits of 5X to 14X
What You Should Know:
- New data from Tufts and Medable reveal on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines and can achieve net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively.
- The findings are based on financial modeling and analysis of trial data from the Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine, and more than 150 clinical trials
Read More
GSK Launches Accelerated Clinical Trial with Tempus
What You Should Know:
- Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022.
- This trial’s data-driven design and site selection
Read More
Sanofi Taps BrightInsight for Development of Software as a Medical Device
What You Should Know:
- Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products.
- The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More
PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer
What You Should Know:
- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients.
- PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More
